European Journal of Pharmacology · 2022 · 38 citations · 36 references
Life SciencesBioinformaticsPharmacologyDrug DiscoveryMolecular PharmacologyNetwork BiologyDisease Network BiologyDrug-target Interaction MappingDrug-target Interaction NetworksMolecular Interaction NetworksNetwork MedicineNetwork PharmacologyActive Ingredient IdentificationDrug - Target Network AnalysisDrug-target Network AnalysisDrug-target Network ConstructionGene Ontology PredictionNetwork-based Drug DiscoveryPharmacological Network AnalysisProtein-protein Interaction Network Analysis
We aimed to identify the active ingredients and elucidate the underlying mechanism of action of Atractylodes lancea (Thunb.) DC (namely, Cangzhu) for the treatment of gouty arthritis (GA) based on network pharmacology methods. These findings are expected to provide a theoretical basis for the clinical treatment of GA. We used monosodium urate (MSU)-induced GA rats as a model to test the overall efficacy of Cangzhu in vivo. Then, the components of the Cangzhu decoction were analyzed and identified, and we screened the active ingredients and their targets. The GA disease targets were predicted by GeneCards and Disgenet databases and found to overlap in both databases. The STRING database was used to construct a protein–protein interaction network, followed by identification of the hub genes using Network Analyzer. Thereafter, Cytoscape software (version 3.8.2) was applied to construct a network for drug-active ingredient-key targets. Next, we applied cluego, a plug-in of Cytoscape, to perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) signal pathway enrichment analyses. Additionally, molecular docking was used to verify the characteristics of the key candidate components interacting with the hub therapeutic targets. Finally, we established an inflammatory injury model of LPS using RAW264.7 macrophages and used it to experimentally validate the critical active ingredients. Cangzhu effectively protected against gouty arthritis in vivo, and network pharmacology results revealed various active ingredients in Cangzhu, such as wogonin, atractylenolide I and atractylenolide II. These compounds were found to act on 16 hub targets, including tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), interleukin-1β (IL-1β), prostaglandin-endoperoxide synthase 2 (PTGS2), recombinant mitogen-activated protein kinase 14 (MAPK14) and transcription factor p65 (RELA), which have significant effects on regulating inflammatory factors and apoptosis-related pathways to improve the proinflammatory or anti-inflammatory imbalance in the body, and this may be one of the underlying mechanisms of Cangzhu in anti-GA. Our findings revealed that Cangzhu comprises multiple active components that exert various targeted effects during GA treatment. These findings provide relevant insights to illuminate the mechanism of Cangzhu in the treatment of GA and provide a reference for further experimental research.
36
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf
Sanjeev Mariathasan, Kim Newton, Denise M. Monack et al. · Nature · 2004 · 1.8K citations
A pilot study of IL-1 inhibition by anakinra in acute gout
Alexander So, Thibaut De Smedt, Sylvie Revaz et al. · Arthritis Research & Therapy · 2007 · 723 citations · Full text
Medicine, Immunology, Pharmacology +17
Kenneth R. Hande, Richard M. Noone, William J. Stone · The American Journal of Medicine · 1984 · 673 citations
Serum uric acid and the risk of cardiovascular and renal disease
Claudio Borghi, Thomas Bardin, Jesse Dawson et al. · Journal of Hypertension · 2015 · 463 citations
Medicine, Nephrology, Pharmacology +15